Strategic Partnerships

To develop and provide treatments for neglected tropical diseases (NTDs) and malaria, which are prevalent mainly in emerging and developing countries, we strategically partner with international organizations, academia and research institutions, non-profit organizations (NPOs), and others. We strive for seamless efforts throughout all stages: drug discovery, development, and delivery (ensuring availability in the market and promoting proper use).

In 2010, Eisai signed a joint declaration with the World Health Organization (WHO) regarding the free provision of diethylcarbamazine tablets, a treatment for lymphatic filariasis (LF), and began providing them to the WHO free of charge from 2013. In 2012, we participated as the only Japanese company in the "London Declaration," an international public-private partnership aiming to combat NTDs, along with 12 major global pharmaceutical companies, the Bill & Melinda Gates Foundation, WHO, the US and UK governments, the World Bank, and governments of endemic countries. In 2022, we signed the "Kigali Declaration" towards achieving the "NTDs Roadmap 2021-2030" led by WHO, expressing our commitment to continue supporting the elimination of LF.

Please see here for further details.

Eisai and Drugs for Neglected Diseases initiative (DNDi) have entered into a joint development agreement to create new treatments for mycetoma. DNDi is a non-profit research and development organization that develops safe, effective, and affordable treatments and therapies for people suffering from NTDs. Since then, we have also collaborated on other tropical diseases, including leishmaniasis, and in 2021, we signed a long-term partnership agreement to advance the development of treatments for NTDs.

Please see the following articles for further details.

Eisai has formed a partnership with AAR Japan (Association for Aid and Relief, Japan), an international non-profit organization in Japan that helps refugees, and has been supporting a mycetoma control project in Sudan since 2019. Since the start of activities, we have provided treatment and surgeries to over 190 patients and carried out disease awareness campaigns for more than 2,800 residents. Additionally, with the cooperation of the Institute of Tropical Medicine, Nagasaki University, we have conducted online training sessions for local partner organizations and stakeholders.
Going forward, we aim to provide more comprehensive and sustainable solutions for mycetoma countermeasures and patient support.

Please see the following articles for further details.

Please see here for further details on the research and development partnership with Medicines for Malaria Venture (MMV).